SCHEMBL7754968

SCHEMBL7754968

Cc1cc2c(cc1C13CC1CC/C3=C\c1ccc(C(=O)O)cc1)C(C)(C)CCC2(C)C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 10/20 0.53
RARG P13631 10/20 0.53
RARA P10276 9/20 0.53
RXRA P19793 16/20 0.52
RXRB P28702 6/20 0.52
RXRG P48443 6/20 0.52
CYP26A1 O43174 2/20 0.48
RECQL P46063 2/20 0.48
BLM P54132 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
GMNN O75496 1/20 0.48
USP2 O75604 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7754972 1.00 RARB (0.53) RARBRARGRARARXRARXRB
SCHEMBL7751702 0.89 CYP3A4 (0.43) RARBRARGRARARXRARXRB
SCHEMBL7751700 0.89 CYP3A4 (0.43) RARBRARGRARARXRARXRB
SCHEMBL7757713 0.87 RARA (0.43) RARBRARGRARARXRARXRB
SCHEMBL7757707 0.87 RARA (0.43) RARBRARGRARARXRARXRB
SCHEMBL7755977 0.86 RXRA (0.53) RARBRARGRARARXRARXRB
SCHEMBL7755954 0.86 RXRA (0.53) RARBRARGRARARXRARXRB
SCHEMBL7754746 0.86 RXRA (0.57) RARBRARGRARARXRARXRB
SCHEMBL7754748 0.86 RXRA (0.57) RARBRARGRARARXRARXRB
SCHEMBL7755874 0.81 RXRA (0.47) RARBRARGRARARXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010034448-A1 New compounds, their preparation and use MURRAY ANTHONY (GB) 2001-10-25 US claimed
EP-1077920-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-02-28 EP claimed
WO-1999058487-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-11-18 WO claimed
US-20070185055-A1 Method for treating cachexia with retinoid ligands JIANG GUANG LIANG 2007-08-09 US disclosed
US-20070185055-A1 Method for treating cachexia with retinoid ligands JIANG GUANG LIANG 2007-08-09 US disclosed
US-20010034448-A1 New compounds, their preparation and use MURRAY ANTHONY (GB) 2001-10-25 US disclosed
EP-1077920-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-02-28 EP disclosed
WO-1999058487-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034448-A1 New compounds, their preparation and use GPR119, SLC5A1, SLC5A2 RARB 1627/4885RARG 1630/4885RARA 1387/4885
US-20070185055-A1 Method for treating cachexia with retinoid ligands RXRA, RXRG, RXRB RARB 8/4885RARG 4/4885RARA 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.